130 related articles for article (PubMed ID: 22732416)
21. Biological evaluation of a halogenated triterpenoid, 2α-bromo-dihydrobelulonic acid as inhibitor of human topoisomerase IIα and HeLa cell proliferation.
Ghosh S; Mukhopadhyay S; Sarkar M; Mandal A; Das V; Kumar A; Giri B
Chem Biol Interact; 2017 Apr; 268():68-76. PubMed ID: 28254521
[TBL] [Abstract][Full Text] [Related]
22. Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu-overexpressing cancer cells.
Zhou NN; Tang J; Chen WD; Feng GK; Xie BF; Liu ZC; Yang D; Zhu XF
Life Sci; 2012 May; 90(19-20):770-5. PubMed ID: 22525372
[TBL] [Abstract][Full Text] [Related]
23. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells.
Kim HD; Tomida A; Ogiso Y; Tsuruo T
J Cell Physiol; 1999 Jul; 180(1):97-104. PubMed ID: 10362022
[TBL] [Abstract][Full Text] [Related]
24. Regulation of p38 phosphorylation and topoisomerase IIalpha expression in the B-cell lymphoma line Jiyoye by CD26/dipeptidyl peptidase IV is associated with enhanced in vitro and in vivo sensitivity to doxorubicin.
Yamochi T; Yamochi T; Aytac U; Sato T; Sato K; Ohnuma K; McKee KS; Morimoto C; Dang NH
Cancer Res; 2005 Mar; 65(5):1973-83. PubMed ID: 15753397
[TBL] [Abstract][Full Text] [Related]
25. A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.
Tian C; Ding P; Yuan Z; Li H; Zhao Y; Sun L; Guo Q; Wang Z; Sun L; Zhang L; Jiang Z
Apoptosis; 2015 Dec; 20(12):1599-612. PubMed ID: 26437915
[TBL] [Abstract][Full Text] [Related]
26. Solamargine enhances HER2 expression and increases the susceptibility of human lung cancer H661 and H69 cells to trastuzumab and epirubicin.
Liang CH; Shiu LY; Chang LC; Sheu HM; Tsai EM; Kuo KW
Chem Res Toxicol; 2008 Feb; 21(2):393-9. PubMed ID: 18078328
[TBL] [Abstract][Full Text] [Related]
27. Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells.
Liang CH; Shiu LY; Chang LC; Sheu HM; Kuo KW
Mol Nutr Food Res; 2007 Aug; 51(8):999-1005. PubMed ID: 17639997
[TBL] [Abstract][Full Text] [Related]
28. Plk3 phosphorylates topoisomerase IIalpha at Thr(1342), a site that is not recognized by Plk1.
Iida M; Matsuda M; Komatani H
Biochem J; 2008 Apr; 411(1):27-32. PubMed ID: 18062778
[TBL] [Abstract][Full Text] [Related]
29. Growth suppression of HER2-overexpressing breast cancer cells by berberine via modulation of the HER2/PI3K/Akt signaling pathway.
Kuo HP; Chuang TC; Yeh MH; Hsu SC; Way TD; Chen PY; Wang SS; Chang YH; Kao MC; Liu JY
J Agric Food Chem; 2011 Aug; 59(15):8216-24. PubMed ID: 21699261
[TBL] [Abstract][Full Text] [Related]
30. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex.
Huang L; Shitashige M; Satow R; Honda K; Ono M; Yun J; Tomida A; Tsuruo T; Hirohashi S; Yamada T
Gastroenterology; 2007 Nov; 133(5):1569-78. PubMed ID: 17983804
[TBL] [Abstract][Full Text] [Related]
31. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
32. Constitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicity.
Yang H; Zhao R; Yang HY; Lee MH
Oncogene; 2005 Mar; 24(11):1924-35. PubMed ID: 15688030
[TBL] [Abstract][Full Text] [Related]
33. A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
Patra N; De U; Kang JA; Kim JM; Ahn MY; Lee J; Jung JH; Chung HY; Moon HR; Kim HS
Eur J Pharmacol; 2011 May; 658(2-3):98-107. PubMed ID: 21376033
[TBL] [Abstract][Full Text] [Related]
34. Topoisomerase IIalpha mediates E2F-1-induced chemosensitivity and is a target for p53-mediated transcriptional repression.
Nip J; Hiebert SW
Cell Biochem Biophys; 2000; 33(2):199-207. PubMed ID: 11325040
[TBL] [Abstract][Full Text] [Related]
35. Cryptolepine, a Plant Alkaloid, Inhibits the Growth of Non-Melanoma Skin Cancer Cells through Inhibition of Topoisomerase and Induction of DNA Damage.
Pal HC; Katiyar SK
Molecules; 2016 Dec; 21(12):. PubMed ID: 28009843
[TBL] [Abstract][Full Text] [Related]
36. Loss of O⁶-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Raguz S; Adams C; Masrour N; Rasul S; Papoutsoglou P; Hu Y; Cazzanelli G; Zhou Y; Patel N; Coombes C; Yagüe E
Biochem Pharmacol; 2013 Jan; 85(2):186-96. PubMed ID: 23122841
[TBL] [Abstract][Full Text] [Related]
37. Expression and purification of a soluble ESX-binding core domain of SUR2.
Jeon KH; Jun KY; Kim EY; Kwon Y
Prep Biochem Biotechnol; 2013; 43(4):364-75. PubMed ID: 23464919
[TBL] [Abstract][Full Text] [Related]
38. Loss of protein kinase Cδ/HuR interaction is necessary to doxorubicin resistance in breast cancer cell lines.
Latorre E; Castiglioni I; Gatto P; Carelli S; Quattrone A; Provenzani A
J Pharmacol Exp Ther; 2014 Apr; 349(1):99-106. PubMed ID: 24492650
[TBL] [Abstract][Full Text] [Related]
39. A chromatin remodeling complex regulates topoisomerase IIα function.
Cancer Discov; 2013 Jul; 3(7):OF33. PubMed ID: 23847378
[TBL] [Abstract][Full Text] [Related]
40. BRCA1-mediated ubiquitination inhibits topoisomerase II alpha activity in response to oxidative stress.
Shinagawa H; Miki Y; Yoshida K
Antioxid Redox Signal; 2008 May; 10(5):939-49. PubMed ID: 18162055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]